3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
5
Active not recruiting
4
Recruiting
2
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
98
Gastrointestinal
61
Dermatologic
58
Head & Neck
54
Genitourinary
48
Breast
40
Gynecologic
34
Other solid neoplasm
26
Lymphoid
22
Tumor-Agnostic
12
Plasma cell
9
CNS
9
Sarcoma
8
Other hematologic neoplasm
6
Myeloid
3
Endocrine
2
NET
1
Classical hematology
1
Conditions
Neuroendocrine Tumors
1
Interventions
Everolimus
7
lutetium Lu 177 dotatate
3
lanreotide
3
Erlotinib Hydrochloride
3
surufatinib
2
gallium Ga 68 dotatate
2
dactolisib
2
Sunitinib
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Filgrastim
2
Capecitabine
2
trifluridine tipiracil drug combination
1
tislelizumab
1
telotristat ethyl
1
telotristat
1
pertuzumab
1
pembrolizumab
1
pelcitoclax
1
pegfilgrastim
1
fosbretabulin
1
folfirinox
1
famitinib
1
entinostat
1
arginyllysine
1
amino-acid, glucose, and electrolyte solution
1
alectinib
1
Temozolomide
1
Surveys and Questionnaires
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
pembrolizumab
×
NET
×
Clear all
NCT03190213
2021-06-22
Pembro NEC
University of Utah
Phase 2
Terminated
6 enrolled
13 charts